homeopathic medicine
Drugindividualized homeopathic medicine
NCT Number: NCT00822406
A total of 41 adults with perennial allergic rhinitis were enrolled in a first double-blind placebo-controlled phase for six months, and treated on a weekly basis with sublingual doses of single individualized homeopathic medicines or placebo. After this closed initial phase, all patients were invited to participate in an long-term open-label controlled phase, in that they would receive homeopathic treatment for the maximum period of 36 months, and the results were compared with the improvement of initial phase. Signs and symptoms scores, rescue medication requirements and quality of life were assessed by questionnaires and personal clinical evaluation by a same independent researcher, before and after each phase. Primary and secondary clinical outcome were, respectively, specific and general allergic signs and symptoms scores. Total IgE titles were performed before and after each phase.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
individualized homeopathic medicine
placebo - 6 months
Time frame: 6 months
Time frame: 6 months
University of Sao Paulo
Other
Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02654223
Hypersensitivity, Immune System Diseases
Aranjuez, Madrid, Spain
View Trial DetailsNCT02360072
Asthma, Bronchial Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT03394508
Allergy, Asthma
View Trial DetailsNCT02596321
Allergy, Asthma
Minsk, Belarus
View Trial Details